Bevacizumab News and Research RSS Feed - Bevacizumab News and Research

Bevacizumab is a recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine. Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.
Bevacizumab–erlotinib combined efficacy may depend on VEGF level

Bevacizumab–erlotinib combined efficacy may depend on VEGF level

Bevacizumab may enhance the antitumour activity of erlotinib by increasing the intratumoural concentration of erlotinib in some non-small-cell lung cancers expressing high levels of vascular endothelial growth factor, Japanese researchers report. [More]
Cediranib combined with chemotherapy improves survival in recurrent cervical cancer

Cediranib combined with chemotherapy improves survival in recurrent cervical cancer

For patients with cervical cancer that has recurred after treatment or has spread elsewhere in the body, adding the experimental drug cediranib to standard chemotherapy improves tumour shrinkage and adds a modest improvement in progression-free survival, researchers report at the ESMO 2014 Congress in Madrid. [More]
Survival benefits with erlotinib plus bevacizumab in EGFR-Mutated NSCLC

Survival benefits with erlotinib plus bevacizumab in EGFR-Mutated NSCLC

Combining erlotinib with bevacizumab could prolong progression-free survival in patients being treated for epidermal growth factor receptor-mutated non-small-cell lung cancer, phase II trial results suggest. [More]
Cancer-fighting cocktail shows promising results for advanced cervical cancer

Cancer-fighting cocktail shows promising results for advanced cervical cancer

Combining a standard chemotherapy drug with a second drug that stops cells from dividing improves both the survival and response rates for those with advanced cervical cancer, a new study by UT Southwestern Medical Center cancer researchers finds. [More]
Cochrane Review rejects safety concerns regarding cheap alternative drug for treating eye disease

Cochrane Review rejects safety concerns regarding cheap alternative drug for treating eye disease

Health policies which favour using ranibizumab for treating eye disease in older people over safety concerns for a cheaper alternative should take account of a new Cochrane Review published today. [More]
Ramucirumab Phase III study meets primary endpoint in patients with metastatic colorectal cancer

Ramucirumab Phase III study meets primary endpoint in patients with metastatic colorectal cancer

Eli Lilly and Company today announced that the RAISE trial, a Phase III study of ramucirumab (CYRAMZA) in combination with chemotherapy in patients with metastatic colorectal cancer (mCRC), met its primary endpoint of overall survival. [More]
Study could lead to improvements in outcomes for women with triple-negative breast cancer

Study could lead to improvements in outcomes for women with triple-negative breast cancer

William M. Sikov, a medical oncologist in the Breast Health Center and associate director for clinical research in the Program in Women's Oncology at Women & Infants Hospital of Rhode Island, served as study chair and lead author for a recently-published major national study that could lead to improvements in outcomes for women with triple-negative breast cancer, an aggressive form of the disease that disproportionately affects younger women. [More]
Study: Brain tumors hijack the brain's existing blood supply during progression

Study: Brain tumors hijack the brain's existing blood supply during progression

Dangerous brain tumors hijack the brain's existing blood supply throughout their progression, by growing only within narrow potential spaces between and along the brain's thousands of small blood vessels, new research shows for the first time. [More]
Elderly mRCC patients should not be excluded from targeted therapy option

Elderly mRCC patients should not be excluded from targeted therapy option

Advanced age is not a reason to preclude patients from receiving vascular endothelial growth factor-targeted therapy for metastatic renal cell carcinoma, show study findings from a mixed-age patient population. [More]
Prophage autologous cancer vaccine extends survival in patients with newly diagnosed GBM

Prophage autologous cancer vaccine extends survival in patients with newly diagnosed GBM

Agenus Inc., announced final results from a single-arm, multi-institutional, open-label, Phase 2 study showing that patients with newly diagnosed glioblastoma multiforme (GBM) who received Agenus' Prophage autologous cancer vaccine added to the standard of care treatment, lived nearly twice as long as expected. [More]
Phase III TAS-102 study for metastatic colorectal cancer shows improved survival

Phase III TAS-102 study for metastatic colorectal cancer shows improved survival

The new combination agent TAS-102 is able to improve overall survival compared to placebo in patients whose metastatic colorectal cancer is refractory to standard therapies, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona. [More]
patients with KRAS wild-type MCRC can benefit from Cetuximab Or Bevacizumab With Combi Chemo Equivalent For patients with KRAS wild-type MCRC

patients with KRAS wild-type MCRC can benefit from Cetuximab Or Bevacizumab With Combi Chemo Equivalent For patients with KRAS wild-type MCRC

For patients with KRAS wild-type untreated colorectal cancer, adding cetuximab or bevacizumab to combination chemotherapy offers equivalent survival, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona. [More]
Six-gene signature predicts survival after targeted therapy for NSCLC

Six-gene signature predicts survival after targeted therapy for NSCLC

The presence of a six-gene profile in the microRNA of patients with advanced non-squamous non-small-cell lung cancer predicts reduced survival likelihood after first-line treatment with targeted therapy followed by chemotherapy for disease progression, indicate research results. [More]
New treatment for ovarian cancer can improve response rates

New treatment for ovarian cancer can improve response rates

Doctors at the University of Arizona Cancer Center at St. Joseph's Hospital and Medical Center in Phoenix reported today in Lancet Oncology that a new treatment for ovarian cancer can improve response rates (increase the rate of tumor shrinkage) and prolong the time until cancers recur. [More]
Avastin and cetuximab extend life of patients with KRAS wild-type advanced bowel cancer

Avastin and cetuximab extend life of patients with KRAS wild-type advanced bowel cancer

CALGB 80405, a large, independent, phase III study, designed to assess the superiority in overall survival (OS) of cetuximab over Avastin (bevacizumab) when combined with either FOLFOX or FOLFIRI chemotherapy in people with previously untreated, KRAS wild-type advanced (metastatic) bowel cancer has failed to meet this primary endpoint. [More]
Ovarian cancer patients with molecular subtypes benefit from bevacizumab

Ovarian cancer patients with molecular subtypes benefit from bevacizumab

Molecular sequencing could identify ovarian cancer patients who are most likely to benefit from treatment with bevacizumab (Avastin), a Mayo Clinic-led study has found. [More]
Nektar reports etirinotecan pegol Phase 2 study results in patients with Avastin-refractory high-grade glioma

Nektar reports etirinotecan pegol Phase 2 study results in patients with Avastin-refractory high-grade glioma

Nektar Therapeutics announced today new data from an investigator-sponsored Phase 2 study of NKTR-102 (etirinotecan pegol) in patients with Avastin-refractory high-grade glioma conducted at Stanford Cancer Institute under the direction of Lawrence Recht, M.D., Professor of Neurology and Neurosurgery, with co-investigator Seema Nagpal, M.D., Clinical Assistant Professor of Neurology and Neurological Sciences, Stanford School of Medicine. [More]
Amgen presents extended analysis of PEAK study data at ASCO

Amgen presents extended analysis of PEAK study data at ASCO

Amgen today announced results from the Phase 2 PEAK study that reinforce the improved overall survival (OS) benefit of panitumumab (Vectibix®) when used in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, compared to bevacizumab (Avastin) plus FOLFOX as first-line treatment in patients with wild-type RAS metastatic colorectal cancer (mCRC). [More]
ASCO: DelMar presents interim data from VAL-083 clinical trial in refractory GBM

ASCO: DelMar presents interim data from VAL-083 clinical trial in refractory GBM

DelMar Pharmaceuticals, Inc. announced the presentation of interim clinical data from the company's ongoing clinical trial with VAL-083 in refractory glioblastoma multiforme (GBM) during the Central Nervous System Tumor Session at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), which is being held at the McCormick Place Convention Center in Chicago. [More]
Multiple lines of targeted therapy extend life for mRCC patients

Multiple lines of targeted therapy extend life for mRCC patients

Overall survival of patients with metastatic renal cell carcinoma is extended the more lines of targeted therapy they receive, shows an evaluation of a large retrospective multicentre database. [More]